Nurse-led discharge education may cut heart failure readmissions
NCT ID NCT07706543
First seen Jul 15, 2026 · Last updated Jul 16, 2026 · Updated 1 time
Summary
This study tests whether a nurse-led discharge education program helps heart failure patients avoid unplanned hospital readmissions within 30 days. The program includes an educational assessment, a discharge session using the teach-back method, and a follow-up phone call. Researchers compare patients who receive this program with those who get standard care. The goal is to improve self-care and reduce readmissions.
What this could mean
Our plain-language read of the trial. This is informational only, not medical advice or a prediction.
- Active substance
- nurse-led discharge education program
- What this could lead to
- If effective, this program could reduce hospital readmissions and improve self-care for heart failure patients.
- What could go wrong
- This is a before-and-after study, not a randomized trial, so results may be influenced by other factors. The program may not work in all hospital settings.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Phase
-
Not a phased trial
Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.
- Participants
-
About 412 people
The number the study aims to enrol. It can still change while the study runs.
- Expected to start
-
Sep 2026
An estimate. Start dates often move.
- Expected to finish
-
Apr 2028
An estimate. End dates often move.
- Lead sponsor
-
Other sponsor
The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
- Ages
-
18 years and older
- Sex
-
Anyone
- Healthy volunteers
-
Not accepted
This study is not open to healthy volunteers. The entry requirements below say who it is open to.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: * Patient aged 18 years old or more, * Fluent in spoken and written French, * Willing to participate in the study, * Hospitalized for heart failure in one of the participating centers for at least 2 days, * Affiliated with a French social security scheme * Discharged either to home or transferred to a Medical and Rehabilitation Care unit. Exclusion Criteria: * Hospitalized for a reason other than heart failure, * Previously included in the study during a prior hospitalization, * Presenting with identified cognitive impairment, * In a situation deemed inappropriate by the care team (end of life), * Living in an institutional setting, * Pregnant women, * Breastfeeding women, * Under legal protective measures, * Enrolled in another interventional research study that may interfere with the results of the present study, according to the investigator's judgment.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Heart failure are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
How to take part
Only the study team decides who joins. These are the ways to reach them.
-
The places running it
3 sites. The list below names each one and where it is.
-
The official record
ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.
-
A doctor treating you
A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.
Contacts and locations
Locations
-
CH Vichy
Vichy, France
-
CHU Clermont-Ferrand
Clermont-Ferrand, France
-
CHU Poitiers
Poitiers, France
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Which SGLT2 inhibitor wins? trial pits empagliflozin against dapagliflozin
- Can daily mindful breathing ease heart failure symptoms?
- Can a smartphone app keep heart failure patients out of the hospital?
- Can better training get doctors to talk about what matters most to dying veterans?
- Can AI read heart ultrasounds as well as trained sonographers?
- Can modern heart failure drugs reverse damage in three months?